Abstract
In the January 2016 issue of Cytotherapy (volume 18 number 1), the International Society for Cell Therapy (ISCT) Presidential Task Force on Unproven Cellular Therapies presented a series of articles addressing issues around the use of unproven cellular therapies. Although the topic is covered extensively, input from patients and patient advocacy groups is lacking. I strongly agree that in the long term, it would be ideal to have clinical trials performed under rigorous regulatory oversight with state-of-the-art manufacturing. However, for many patients with debilitating diseases, this does not currently provide an immediate solution for treatment or an avenue to cure. This unmet need drives patients to seek treatment offshore or from providers working outside the regulatory framework. So, in addition to defining the issues around unproven cellular therapies, there remains a need to provide access to stem cell and other cellular therapies for today's patients.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call